CGS the quiet achiever, no pull back after the last cap raise. Bioshares did another review 2 weeks ago, going over the status of ALZ trials and prospects, a few excerpts:
Advancing knowledge andpositive progress in drug development for what has to date beenan intractable disease, will likely see a big lift in activity in drugdevelopment over the next three years. If Biogen/Eisai'saducanumab reaches the market, companies such as these willneed a triaging tool to help establish which patients with cognitivedecline may have early Alzheimer's disease, which will requirea PET scan for confirmation prior to drug treatment, and whichpeople are simply slowing down and occasionally forget wherethey have placed their car keys.
With the momentum turning with a series of positivedevelopments in the Alzheimer's disease drug development space,Cogstate's share price has bottomed and should be in a strongcorrection phase over the medium term.
Spec Buy Class A
CGS Price at posting:
40.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)